News

Home/News
News 2017-06-21T13:15:59+00:00
February 21, 2018
Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting
VANCOUVER, Feb. 21, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
February 21, 2018
STRATA Skin Sciences, Inc. to Report 4th Quarter and Fiscal 2017 Financial Results on Thursday, March 8
HORSHAM, Pa., Feb. 21, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to ...
February 21, 2018
La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, ...
February 20, 2018
Zealand Pharma and UniQuest collaborate to develop novel drug candidates for gastrointestinal diseases
Copenhagen, Denmark, and Brisbane, Australia, February 20, 2018 - Zealand Pharma A/S ("Zealand") and UniQuest - the commercialisation company of The University of Queensland (UQ) ...
February 20, 2018
Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its pivotal Phase 3 PALISADE efficacy ...
February 20, 2018
CorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin(R) for Interim Efficacy Analysis
BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 20, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
February 20, 2018
Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
February 20, 2018
DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)
CUPERTINO, Calif., Feb. 20, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary ...
February 15, 2018
Ohr Pharmaceutical Reports Fiscal First Quarter 2018 Financial Results
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results and ...
February 15, 2018
Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update
DUBLIN, Ireland, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of ...
February 15, 2018
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results
VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 14, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on ...
February 15, 2018
Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases
Pratteln, Switzerland, February 15, 2018 - Santhera Pharmaceuticals (SANN.SW) announces that it has entered into a license agreement with Polyphor Ltd. for POL6014, a clinical stage ...
February 15, 2018
VALNEVA Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Lyon (France), February 15, 2018 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing and commercializing innovative, ...
February 15, 2018
Addex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors
Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (ADXN.SW), the leading developer of oral allosteric modulators for neurological disorders, announced today that the Board of ...
February 15, 2018
Zealand Pharma's dasiglucagon Phase 2a results at the 11th International Conference on ATTD
Copenhagen, February 15, 2018 - Dr. Steven J. Russell, Massachusetts General Hospital, Boston, U.S., principal investigator for Zealand Pharma`s ("Zealand") Phase 2a trial of dasiglucagon in ...
February 15, 2018
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
MONMOUTH JUNCTION, N.J., Feb. 15, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac ...
February 15, 2018
Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that two abstracts have ...
February 15, 2018
Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and ...
February 15, 2018
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018
BOSTON, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...
February 15, 2018
Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)
LAVAL, QC, Feb. 15, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic") announced today that an orphan drug designation status has been granted to ...
Page 18 of 70